版本:
中国

BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib

April 25 Galapagos Nv:

* Galapagos announces new phase 2 proof-of-concept study with filgotinib in cutaneous lupus erythematosus

* Says study is being led by filgotinib collaboration partner Gilead Sciences Inc Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐